CN Mobile Logo

Search form


DaunoXome Cleared For Kaposi's Sarcoma

DaunoXome Cleared For Kaposi's Sarcoma

BOULDER, Colorado--NeXstar Pharmaceutical's DaunoXome (dauno-rubicin citrate liposome injection) has received FDA approval for use as primary therapy for advanced HIV-associated Kaposi's sarcoma (KS).

In the company-sponsored phase III trial, conducted at 13 US and Canadian centers and involving 227 patients with advanced HIV-associated KS, Dauno-Xome was found to have efficacy comparable to the three-drug regimen of Adria-mycin, bleomycin, and vincristine (ABV).

Average survival was 342 days for patients on DaunoXome vs 291 days for those on ABV. Side effects such as neu-ropathy and alopecia were reduced significantly with use of DaunoXome.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.